0Y5E Stock Overview
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Perrigo Company plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.51 |
| 52 Week High | US$40.01 |
| 52 Week Low | US$25.78 |
| Beta | 0.65 |
| 1 Month Change | -3.27% |
| 3 Month Change | -8.32% |
| 1 Year Change | -17.10% |
| 3 Year Change | -28.03% |
| 5 Year Change | -37.29% |
| Change since IPO | -66.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Y5E | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.07% | -1.3% | -0.9% |
| 1Y | -17.1% | -5.5% | -1.8% |
Return vs Industry: 0Y5E underperformed the UK Pharmaceuticals industry which returned -5.5% over the past year.
Return vs Market: 0Y5E underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0Y5E volatility | |
|---|---|
| 0Y5E Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0Y5E has not had significant price volatility in the past 3 months.
Volatility Over Time: 0Y5E's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 9,140 | Patrick Lockwood-Taylor | www.perrigo.com |
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Perrigo Company plc Fundamentals Summary
| 0Y5E fundamental statistics | |
|---|---|
| Market cap | US$4.17b |
| Earnings (TTM) | -US$4.40m |
| Revenue (TTM) | US$4.66b |
0.9x
P/S Ratio-948.6x
P/E RatioIs 0Y5E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Y5E income statement (TTM) | |
|---|---|
| Revenue | US$4.66b |
| Cost of Revenue | US$2.98b |
| Gross Profit | US$1.68b |
| Other Expenses | US$1.68b |
| Earnings | -US$4.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 36.09% |
| Net Profit Margin | -0.094% |
| Debt/Equity Ratio | 85.4% |
How did 0Y5E perform over the long term?
See historical performance and comparison